Stifel Financial Corp Acquires 226 Shares of Repligen Co. (NASDAQ:RGEN)

Stifel Financial Corp increased its holdings in Repligen Co. (NASDAQ:RGEN) by 5.4% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 4,404 shares of the biotechnology company’s stock after buying an additional 226 shares during the quarter. Stifel Financial Corp’s holdings in Repligen were worth $655,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of RGEN. Andra AP fonden purchased a new stake in Repligen in the second quarter worth approximately $25,000. UMB Bank n.a. grew its stake in shares of Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 130 shares during the period. Blue Trust Inc. increased its position in shares of Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 127 shares during the last quarter. International Assets Investment Management LLC bought a new position in Repligen in the second quarter worth approximately $33,000. Finally, Quarry LP raised its holdings in Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 239 shares during the period. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Wolfe Research initiated coverage on Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. StockNews.com cut shares of Repligen from a “hold” rating to a “sell” rating in a research report on Thursday, December 19th. Finally, Canaccord Genuity Group began coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. One analyst has rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $185.20.

Repligen Price Performance

Repligen stock opened at $146.95 on Thursday. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The firm’s fifty day moving average is $144.27 and its 200 day moving average is $141.66. The company has a market cap of $8.23 billion, a price-to-earnings ratio of -397.15, a PEG ratio of 4.64 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million for the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business’s revenue was up 9.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.23 EPS. Sell-side analysts forecast that Repligen Co. will post 1.54 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.